India’s first dengue vaccine, Qdenga, is expected to be available in the country in the first half of 2027, according to infectious diseases expert Chandrakant Lahariya. The vaccine is likely to be introduced initially through private healthcare settings, marking a significant step in dengue prevention efforts in India, which faces seasonal outbreaks of the disease, according to livemint.com.
The announcement about Qdenga’s expected arrival came via Lahariya’s WhatsApp channel this week, highlighting the vaccine’s pending approval and distribution plans. An infographic accompanying the report clarified that Qdenga is not yet available in India but is anticipated to be accessible early next year. The vaccine has been developed to target all four dengue virus serotypes, aiming to reduce the incidence and severity of dengue infections.
Dengue remains a major public health challenge in India, with periodic outbreaks causing significant morbidity. The introduction of Qdenga could provide a new tool for controlling the disease, especially in urban and semi-urban areas where dengue transmission is high. Globally, dengue vaccines have faced challenges related to safety and efficacy, but Qdenga’s approval in other countries has shown promising results in preventing dengue fever and its severe forms.
The rollout of Qdenga in India will be closely watched by healthcare providers and public health officials. The vaccine’s availability in private healthcare settings in early 2027 sets a timeline for when patients at risk of dengue may begin receiving immunization, potentially impacting the disease’s seasonal outbreak patterns.